Life Edit Therapeutics
Matt Nethery is a Senior Data Scientist at Life Edit Therapeutics since February 2022, previously holding the position of Data Scientist II. Prior to this role, Matt Nethery worked as a researcher and PhD student in the Barrangou lab at North Carolina State University from August 2016 to February 2022, focusing on CRISPR biology. Matt Nethery's earlier experience includes a decade at Premier Inc. as a Software Engineer, where full stack software systems for healthcare analytics were developed and managed. Matt Nethery obtained a PhD in Functional Genomics with a specialization in Microbial Genetics from North Carolina State University and holds a Bachelor's degree in Computer Information Systems from Appalachian State University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.